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Racial Differences in Clinical Treatment and Self-Care Behaviors of
Adults With Chronic Heart Failure
Victoria Vaughan Dickson, PhD, RN, FAHA, FAAN; George J. Knaﬂ, PhD; Joyce Wald, DO, FACC; Barbara Riegel, PhD, RN, FAHA, FAAN
Background-—In the United States, the highest prevalence of heart failure (HF) is in blacks followed by whites. Compared with
whites, blacks have a higher risk of HF-related morbidity and mortality and HF-related hospitalization. Little research has focused
on explaining the reasons for these disparities. The purpose of this study was to examine racial differences in demographic and
clinical characteristics in blacks and whites with HF and to determine if these characteristics inﬂuenced treatment, or together with
treatment, inﬂuenced self-care behaviors.
Methods and Results-—This was a secondary analysis of existing data collected from adults (n=272) with chronic HF enrolled from
outpatient sites in the northeastern United States and followed for 6 months. After adjusting for sociodemographic and clinical
characteristics within reduced (HFrEF) and preserved ejection fraction (HFpEF) groups, there were 2 signiﬁcant racial differences in
clinical treatment. Blacks with HFrEF were prescribed ACE inhibitors and hydralazine and isosorbide dinitrate (H-ISDN) more often
than whites. In the HFpEF group, blacks were taking more medications and were prescribed digoxin and a diuretic when
symptomatic. Deﬁcits in HF knowledge and decreased medication adherence, objectively measured, were more prominent in
blacks. These racial differences were not explained by sociodemographic or clinical characteristics or clinical treatment variables.
Premorbid intellect and the quality of support received contributed to clinical treatment and self-care.
Conclusion-—Although few differences in clinical treatment could be attributed solely to race, knowledge about HF and medication
adherence is lower in blacks than whites. Further research is needed to explain these observations, which may be targets for future
intervention research. ( J Am Heart Assoc. 2015;4:e001561 doi: 10.1161/JAHA.114.001561)
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T he epidemic of heart failure (HF) has captured theattention of investigators worldwide.1 In the United
States, where this study was conducted, an estimated 5.7
million adults have HF.2 Changing demographics in the United
States include a growing cohort of ethnic minority groups,
which contributes to the HF epidemic. Among the various
racial and ethnic minority groups in the United States, the
highest prevalence of HF is found in blacks (3.6% of US
blacks) followed by whites (2.4% of US whites).3 Compared
with whites, racial and ethnic minority patients have a 2.5
times greater risk of HF-related mortality and a 42% higher
risk of HF-related hospitalization.4,5 Yet, little research has
focused on explaining the reasons for these disparities. The
purpose of this study was to examine racial differences in
demographic and clinical characteristics in blacks and whites
with HF and to determine if these characteristics inﬂuenced
treatment, or together with treatment, inﬂuenced self-care
behaviors.
Racial Differences in the Clinical Treatment of
Heart Failure
Clinical guidelines specify the appropriate pharmacologic
regimen for patients with HF including use of angiotensin-
converting-enzyme (ACE) inhibitors, beta-blockers and angio-
tensin receptor blockers (ARBs) for those with reduced
ejection fraction HF (HFrEF).6 Some early evidence suggests
that beta-blockers may be less effective in preventing death
or hospitalization in black HF patients than in whites, but
further evidence is needed before practice is modiﬁed.7
From the New York University College of Nursing, New York, NY (V.V.D.);
University of North Carolina, School of Nursing, Chapel Hill, NC (G.J.K.); Heart
Failure Transplant Program, University of Pennsylvania, Philadelphia, PA (J.W.);
University of Pennsylvania, School of Nursing Philadelphia PA (B.R.).
An accompanying Appendix S1 is available at http://jaha.ahajournals.org/
content/4/4/e001561/suppl/DC1
Correspondence to: Victoria Vaughan Dickson, PhD, RN, FAHA, FAAN, New
York University College of Nursing, 726 Broadway, #1022, New York, NY
10003. E-mail: vdickson@nyu.edu
Received October 27, 2014; accepted March 6, 2015.
ª 2015 The Authors. Published on behalf of the American Heart Association,
Inc., by Wiley Blackwell. This is an open access article under the terms of the
Creative Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original work is
properly cited and is not used for commercial purposes.
DOI: 10.1161/JAHA.114.001561 Journal of the American Heart Association 1
ORIGINAL RESEARCH
 by guest on A
ugust 20, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Angiotensin receptor blockers (ARBs) are prescribed for HFrEF
patients intolerant to ACE inhibitors; one reason for intoler-
ance is angioedema, which occurs more frequently in blacks.8
Although few clinical trials have focused on patients with
preserved ejection fraction HF (HFpEF), clinical guidelines
advocate using basically the same approach as for those with
HFrEF.6
In recent years there has been growing awareness that the
treatment of HF in blacks should be subtly modiﬁed based on
recognition that some blacks have differences in nitric oxide
(NO) homeostasis and impairments in NO-mediated cardio-
vascular effects.9 Recognition of race as a surrogate of this
alternate mechanism has strengthened the evidence support-
ing use of hydralazine and isosorbide dinitrate (H-ISDN) in
combination to target this mechanism.10 H-ISDN is recom-
mended for blacks with HFrEF as an addition, not a substitute
for guideline-driven pharmacotherapy.6
Racial Differences in Self-Care of Heart Failure
Once clinical treatment is prescribed, patients are sent home
to perform self-care. Self-care is deﬁned as a naturalistic
decision-making process that includes self-care maintenance,
those behaviors performed to maintain physiological stability
(eg, treatment adherence), symptom monitoring, and self-care
management or the response to HF symptoms when they
occur.11 Self-care is poor among ethnic and racial minority
populations.12,13 Race has been found to be associated with
poor medication adherence14 and treatment-seeking delays
that result from poor symptom recognition and symptom
interpretation.15 The reason that self-care is poorer in these
populations has been attributed in part to racial differences in
symptom perception,15,16 sociocultural factors that include
health perceptions and level of acculturation,17 provider
interactions,18 and ﬁnancial resources.14,19
There is also growing evidence that comorbid conditions
compound the difﬁculties associated with HF self-care.20,21
Blacks with HF are more likely to have diabetes, hypertension,
and obesity than whites22 and those with both HF and
diabetes report difﬁculty in reconciling dietary instructions,
symptom recognition and symptom management. In addition,
depression is common in blacks with HF23 and associated
with poor self-care.24,25
In summary, considering clinical guidelines, race-related
differences in clinical treatment should be minor, but few
studies have been conducted to defend or refute such a claim.
Studies in other clinical populations suggest that race may be
a factor in self-care,26 but few studies have addressed this
issue in HF self-care. Because so few studies of clinical
treatment or self-care compare racially diverse patients with
HF, the purpose of this study was to examine racial
differences in demographic and clinical characteristics in
blacks and whites with HF. Further, we sought to determine if
sociodemographic and clinical characteristics inﬂuenced
treatment, or together with treatment, inﬂuenced self-care
behaviors.
Materials and Methods
Study Design
This was a secondary analysis of existing data collected for a
prospective cohort study. The methods used in this study
have been detailed previously.27 In brief, the parent descrip-
tive study was performed to explore factors inﬂuencing HF
self-care. Thus, in this analysis, self-care was deﬁned as
encompassing adherence to the clinical treatment regimen
including medications and low-sodium diet, symptom moni-
toring (eg, daily weights), and symptom management.28 Self-
care was measured carefully using both subjective and
objective measures as described below. Data were collected
at baseline, at 3 months, and at 6 months, primarily during
home visits conducted by research assistants. Clinical
information was abstracted from the medical record by
registered nurses.
Study Population
A sample of 280 adults with stable, chronic HF was enrolled
into the parent study. Eight of these individuals self-reported
their ethnicity/race as something other than black or white,
leaving a sample of 272 individuals for the current analysis. All
participants provided informed consent.
Patients were identiﬁed from diverse settings that cared
for ethnically diverse populations and included clinics, physi-
cian ofﬁces, HF specialty clinics, and a Veterans Administra-
tion setting located in the northeastern United States.
Patients were included in the study if they had chronic HF
conﬁrmed based on recent echocardiographic and clinical
evidence. Both reduced and preserved left ventricular ejection
fraction patients were included, but the analysis of clinical
treatment was conducted separately for each group. Other
inclusion criteria were sufﬁcient vision, hearing, and ability to
read and understand English, which was necessary to perform
tests. Patients with severely impaired cognition were
screened out using the Telephone Interview of Cognitive
Status.29 Exclusion criteria were related to the purpose of the
primary study in which daytime sleepiness was explored as a
contributor to HF self-care. So, otherwise eligible patients
were excluded if they worked nights or rotating shifts or lived
in a long-term care setting where self-care was not an
expectation. Those with a major depressive illness or a recent
history of serious drug or alcohol abuse were not enrolled.
Major depressive illness was screened in the medical
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record and with administration of the 9-item Patient Health
Questionnaire (PHQ-9).30 Individuals with a PHQ-9 score >10
were excluded but only if depressed mood or anhedonia was
reported, to minimize the risk of excluding someone with HF
symptoms that mimicked depression.
Measurement
Demographic data were collected by survey. Social support was
measured with the Multidimensional Scale of Perceived Social
Support.31 Knowledge about HF was assessed using the Dutch
HF Knowledge Scale,32 which assesses knowledge of HF in
general, knowledge of HF treatment and HF symptoms. The
Dutch HF Knowledge Scale has been used in numerous US-
based studies including our own.33,34 The American National
Adult Reading Test (ANART) was used to measure premorbid
intellect.35 Intellect refers to the ability to learn and to deal with
new situations and to deal effectively with tasks involving
abstract thinking. Premorbid intellect is thought to be spared
following cognitive decline. In measuring premorbid intellect
with the ANART, participants were asked to pronounce aloud 50
irregular words (eg, capon, blatant, debt). The number
pronounced correctly was used in analysis. Clinical data on
the number of major comorbid conditions (eg, diabetes,
arthritis, hypertension) were abstracted from the medical
record. New York Heart Association (NYHA) functional class
was assessed by standardized interview36 and scored by a
single cardiologist. Self-care was assessed by self-report using
the Self-Care of HF Index v.6.2.37 Objective measures of self-
care included 24-hour urine samples, which were obtained to
allow calculation of urinary sodium excretion to indicate salt-
restricted diet adherence.38 Medication adherence was mon-
itored for 6 months using the medication event monitoring
system (MEMS; MVW Switzerland Ltd, Sion, Switzerland).39 All
data were collected between 2007 and 2009.
Statistical Analysis
Most of the data for this analysis were categorical, but before
analysis began continuous data were categorized using
standard cut-points. For example, the standardized scores
on the Self-Care of HF Index scales are considered to reﬂect
inadequate self-care if <70.37 Most variables were dichoto-
mous, but variables with 3 levels were represented in the
analyses described below with indicators for the ﬁrst 2 levels
shown in associated tables.
The Appendix S1 contains a detailed description of the
analysis process. An overview of that process is provided
here. First, unadjusted racial differences in individual soci-
odemographic and clinical characteristics were identiﬁed
(using v2 tests if all expected cell counts were at least 5;
otherwise using Fisher’s exact test). Then, unadjusted racial
differences in individual clinical treatment variables were
identiﬁed (using v2 or Fisher’s exact tests). These differences
were further investigated (as described in the Appendix S1)
using adaptive logistic regression models40 adjusting for
sociodemographic and clinical characteristics holding the race
effect ﬁxed in the model and testing the race effect in the
resulting model (using a Wald v2 test). These analyses were
conducted separately for HFrEF and HFpEF patients to
account for possible differences in their clinical treatment.
Finally, unadjusted racial differences in individual self-care
variables were identiﬁed (using v2 or Fisher’s exact tests), and
these were further investigated using adaptive logistic
regression models by adjusting ﬁrst for sociodemographic
and clinical characteristics and then for clinical treatment
variables.
Results
Unadjusted Racial Differences
Of the 272 participants, 176 (64.7%) were white while the
other 96 (35.3%) were black.
Sociodemographic and clinical characteristics
The participants’ sociodemographic and clinical characteris-
tics are shown in Tables 1 and 2. In unadjusted comparative
analyses based on race, blacks with HF were more likely than
whites with HF to be younger, less well educated, lower in
premorbid intellect, disabled, living with inadequate income,
and insured by the government or uninsured (Table 1). Blacks
were more likely to be unmarried and to perceive lower levels
of social support and lower quality of support. Considering
clinical characteristics, blacks were more likely than whites to
have HF of nonischemic etiology and to be in NYHA class IV
(Table 2). Blacks were less likely than whites to report
drinking 3 or more alcoholic drinks per day but more likely to
be current smokers and to be severely obese with a body
mass index (BMI) >35. Blacks were more likely to be
depressed and to have a high number of comorbid conditions
including anemia, diabetes mellitus, hypertension, and renal
disease.
Clinical treatment of heart failure for HFrEF patients
For the 220 HFrEF patients (84 or 38.2% black), there were no
racial differences in the likelihood of being treated by a HF
specialist (Table 3). Participants with HFrEF were prescribed a
substantial amount of medication each day in both total
number of medications (M=9.8, SD=3.7, n=220) and medi-
cation doses (M=12.9, SD=5.5, n=201). Blacks were less
likely to be prescribed an ACE inhibitor but more likely to be
prescribed H-ISDN. Blacks were also more likely to be
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Table 1. Sociodemographic Characteristics by Race
Variable
n (%)
P Value*Black White
Age (n=272) 0.048
≥60 51 (53.1) 115 (65.3)
<60 45 (46.9) 61 (34.7)
Gender (n=272) 0.640
Male 60 (62.5) 115 (65.3)
Female 36 (37.5) 61 (34.7)
Premorbid intellect (n=270) <0.001
ANART≤25 59 (62.8) 31 (17.6)
25<ANART≤36 27 (28.7) 62 (35.2)
ANART>36 8 (8.5) 83 (47.2)
Education (n=272) 0.004
≤12 years (at most high school) 55 (57.3) 74 (42.0)
13 to 16 years (some college) 35 (36.5) 66 (37.5)
>16 years (graduate study) 6 (6.2) 36 (20.5)
Employment status (n=272) 0.001
Employed full or part-time 17 (17.7) 59 (33.5)
Disabled due to HF 31 (32.3) 26 (14.8)
Unemployed by choice,
homemaker, or retired due to HF
48 (50.0) 91 (51.7)
Household income (n=272) <0.001
Not enough 31 (32.3) 13 (7.4)
Enough 46 (47.9) 86 (48.9)
More than enough 19 (19.8) 77 (43.7)
Health insurance (n=272) 0.001
Government or uninsured† 65 (67.7) 83 (47.2)
Commercial or HMO 31 (32.3) 93 (52.8)
Marital status (n=272) <0.001
Single, divorced, separated, or widowed 59 (61.5) 59 (33.5)
Married or partnered 37 (38.5) 117 (66.5)
Living situation (n=272) 0.087
Living with others 70 (72.9) 144 (81.8)
Living alone 26 (27.1) 32 (18.2)
Social support (n=262) 0.032
MSPSS≤70 38 (41.8) 49 (28.7)
MSPSS>70 53 (58.2) 122 (71.3)
Quality of support (n=272) 0.009
Satisfactory 16 (16.7) 15 (8.5)
Good 31 (32.3) 39 (22.2)
Very good 49 (51.0) 122 (69.3)
ANART indicates American National Adult Reading Test; HF, heart failure; HMO, health maintenance organization; MSPSS, Multidimensional Scale of Perceived Social Support.
*Reported P-values are for associated v2 tests.
†This includes 3 patients with no insurance.
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Table 2. Clinical Characteristics by Race
Variable
n (%)
P Value*Black White
HF type (n=271) 0.223
Systolic or mixed 74 (77.1) 146 (83.0)
Diastolic 22 (22.9) 30 (17.0)
Months with HF (n=253) 0.836
≤24 26 (28.3) 44 (27.3)
25 to 60 22 (23.9) 44 (27.3)
>60 44 (47.8) 73 (45.4)
NYHA functional class (n=272) 0.001
IV 28 (29.2) 21 (11.9)
III 53 (55.2) 107 (60.8)
I to II 15 (15.6) 48 (27.3)
HF etiology (n=271) 0.017
Ischemic 25 (26.3) 72 (40.9)
Nonisichemic 70 (73.7) 104 (59.1)
Alcohol consumption (n=272) 0.001
3 or more drinks 4 (4.2) 34 (19.3)
2 or less drinks 92 (95.8) 142 (80.7)
Body mass index (n=271) 0.003
>35 34 (35.8) 32 (18.2)
26 to 35 43 (45.3) 89 (50.6)
≤25 18 (18.9) 55 (31.2)
Smoking history (n=272) 0.050
Currently smoking 15 (15.6) 14 (8.0)
Current not smoking 81 (84.4) 162 (92.0)
Depression (n=272) 0.024
PHQ 9>5 39 (40.6) 48 (27.3)
PHQ 9≤5 57 (59.4) 128 (72.7)
Number of comorbid conditions (n=272) 0.001
>4 33 (34.4) 31 (17.6)
3 to 4 37 (38.5) 59 (33.5)
0 to 2 26 (27.1) 86 (48.9)
History of anemia (n=268) 0.014
Yes 24 (25.3) 23 (13.3)
No 71 (74.7) 150 (86.7)
History of atrial fibrillation (n=271) 0.361
Yes 36 (37.5) 56 (32.0)
No 60 (62.5) 119 (68.0)
History of diabetes mellitus (n=272) 0.009
Yes 43 (44.8) 51 (29.0)
No 53 (55.2) 125 (71.0)
Continued
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prescribed a diuretic when symptomatic (NYHA class II to IV)
than whites.
Clinical treatment of heart failure for HFpEF patients
For the 52 HFpEF patients (22 or 42.3% black), there were no
racial differences in the likelihood of being treated by a HF
specialist (Table 4). Participants with HFpEF were prescribed
a substantial amount of medication each day in both total
number of medications (M=10.4 SD=4.9, n=52) and medica-
tion doses (M=14.6, SD=6.9, n=45). Blacks were more likely
than whites to be taking multiple medications (>8) daily.
However, blacks were less likely to be prescribed digoxin (no
blacks with HFpEF were prescribed digoxin so Fisher’s exact
test was used) but more likely to be prescribed a diuretic
when symptomatic (NYHA class II to IV) than whites.
Heart failure self-care
Racial differences in the self-care variables for both HFpEF
and HFrEF patients are shown in Table 5. Black patients had
lower HF knowledge scores (Dutch Knowledge of HF Scale
score ≤10), had less medication adherence over 6 months of
follow-up (percent of doses taken [PDT] <88%), and reported
less physical activity (<30 min/week) than whites.
Adjusted Racial Differences
Table 6 contains results for adjusted analyses.
Clinical treatment of heart failure for HFrEF patients
Racial differences in being prescribed an ACE inhibitor
remained signiﬁcant after adjusting for appropriate sociode-
mographic and clinical characteristics. The one determinant of
being prescribed an ACE inhibitor was a rating of social
support quality as only “satisfactory” (the lowest reported
rating) in addition to race.
Racial differences in being prescribed H-ISDN remained
signiﬁcant after adjusting for appropriate sociodemographic
and clinical characteristics. Determinants of H-ISDN included
“good” quality of support and a history of renal disease in
addition to race.
Assuming that diuretics are prescribed only for symptom-
atic patients, we considered race in combination with NYHA
class. Racial differences in being prescribed a diuretic and
having NYHA class II to IV became nonsigniﬁcant after
adjusting for appropriate sociodemographic and clinical
characteristics. In this analysis, determinants were low
premorbid intellect and a history of renal disease.
Clinical treatment of heart failure for HFpEF patients
Racial differences in taking multiple (>8) medications daily
remained signiﬁcant after adjusting for appropriate sociode-
mographic and clinical characteristics. The only other deter-
minant of multiple medications was a history of diabetes
mellitus.
Having a history of atrial ﬁbrillation was the only sociode-
mographic or clinical characteristic signiﬁcantly related to
being prescribed digoxin. It was removed from the model by
backward elimination leaving only a race effect, but the
models considered in this analysis all had questionable ﬁt due
to no blacks being prescribed digoxin and the ﬁnal model had
a nonsigniﬁcant race effect with P=0.941. However, since
race was signiﬁcantly related to being prescribed digoxin
using Fisher’s exact test, which is not affected by ﬁt problems,
racial differences in this case are reasonably considered
signiﬁcant.
Table 2. Continued
Variable
n (%)
P Value*Black White
History of hypertension (n=272) <0.001
Yes 78 (81.3) 97 (55.1)
No 18 (18.7) 79 (44.9)
History of myocardial infarction (n=272) 0.193
Yes 30 (31.3) 69 (39.2)
No 66 (68.7) 107 (60.8)
History of renal disease (n=267) 0.009
Yes 33 (34.4) 34 (19.9)
No 63 (65.6) 137 (80.1)
HF indicates heart failure; NYHA, New York Heart Association.
*Reported P-values are for associated v2 tests.
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Table 3. Clinical Treatment Variables by Race for Patients With Heart Failure With Reduced Ejection Fraction
Variable
n (%)
P Value*Black White
Primary physician provider a HF specialist (n=220) 0.296
Yes 27 (36.5) 64 (43.8)
No 47 (63.5) 82 (56.2)
Total number of medications prescribed to be taken daily (n=220) 0.215
>8 48 (64.9) 82 (56.2)
≤8 26 (35.1) 64 (43.8)
Receiving specialized HF services (n=220) 0.566
Yes 38 (51.4) 69 (47.3)
No 36 (48.6) 77 (52.7)
Receiving home health or visiting nursing care (n=220) 0.106
Yes 12 (16.2) 13 (8.9)
No 62 (83.8) 133 (91.1)
Prescribed an ACE inhibitor (n=220) 0.017
Yes 38 (51.4) 99 (67.8)
No 36 (48.6) 47 (32.2)
Prescribed an aldosterone receptor antagonist (n=220) 0.787
Yes 26 (35.1) 54 (37.0)
No 48 (64.9) 92 (63.0)
Prescribed an angiotension receptor blocker (n=220) 0.129
Yes 26 (35.1) 37 (25.3)
No 48 (64.9) 109 (74.7)
Prescribed an ACE inhibitor and an angiotension receptor blocker (n=220) 0.150
Yes 62 (83.8) 132 (90.4)
No 12 (16.2) 14 (9.6)
Prescribed a beta blocker (n=220) 0.447†
Yes 70 (94.6) 142 (97.3)
No 4 (5.4) 4 (2.7)
Prescribed hydrazaline and isorbide dinitrate (n=220) 0.005
Yes 10 (13.5) 5 (3.4)
No 64 (86.5) 141 (96.6)
Prescribed digoxin (n=220) 0.267
Yes 31 (41.9) 50 (34.2)
No 43 (58.1) 96 (65.8)
Prescribed a diuretic with NYHA ;functional class II to IV (n=220) 0.016
Yes 64 (86.5) 105 (71.9)
No 10 (13.5) 41 (28.1)
Prescribed warfarin (n=220) 0.861
Yes 29 (39.2) 59 (40.4)
No 45 (60.8) 87 (59.6)
Continued
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Again assuming that diuretics are prescribed only for
symptomatic patients, we considered race in combination
with NYHA class. No sociodemographic and clinical
characteristics were signiﬁcantly related to being prescribed
a diuretic and having NYHA class II to IV so that the racial
difference in this clinical treatment variable remained signif-
icant.
Heart failure self-care
Racial differences in HF knowledge scores for both HFpEF and
HFrEF patients remained signiﬁcant after adjusting for
appropriate sociodemographic and clinical characteristics. In
addition to race, the only other determinant of low HF
knowledge was a history of myocardial infarction. The same
model was generated when clinical treatment variables were
also considered.
Racial differences in medication adherence (low with % PDT
<88%) remained signiﬁcant after adjusting for appropriate
sociodemographic and clinical characteristics although a
single clinical characteristic, a history of renal disease, was
also a determinant of poor medication adherence. The same
model was generated when clinical treatment variables were
also considered.
Racial differences in physical activity (exercise <30 min/
week) became nonsigniﬁcant after adjusting for appropriate
sociodemographic and clinical characteristics (and so clinical
treatment variables were not also considered). Low premorbid
intellect and having renal disease explained low levels of
physical activity rather than race.
Discussion
The purpose of this study was to examine racial differences in
demographic and clinical characteristics in blacks and whites
with HF. Further, we sought to determine if sociodemographic
and clinical characteristics inﬂuenced treatment, or together
with treatment, inﬂuenced self-care behaviors. Although we
found notable racial differences in 9 of the 11 sociodemo-
graphic and 11 of 15 clinical characteristics, we found few
differences in clinical treatment that could be attributed
purely to race. Blacks with HFpEF were on more medications,
received digoxin less often and took more diuretics than
whites. The only self-care behaviors that unequivocally
differed by race were knowledge about HF and medication
adherence, which were lower in blacks than in whites. Our
results suggest that blacks may experience a greater disease
burden than whites, which may be complicated by social
disparities.
Although clinical guidelines advocate very similar treat-
ment regimens in blacks and whites, some important
differences in the medication regimens and regimen charac-
teristics were found. Blacks with HFrEF were less likely to be
prescribed an ACE-I and more likely to receive H-ISDN, as
expected, and a diuretic when symptomatic. Perhaps these
differences reﬂect the choice of drugs also appropriate for the
treatment of hypertension as the blacks were more likely to
have hypertension than the whites. Blacks with HFpEF also
were more likely to be prescribed digoxin and diuretics. The
use of digoxin is confusing, because the blacks were not more
likely to have atrial ﬁbrillation. Notably, the blacks were also
signiﬁcantly more likely to be taking more than 8 medications
daily, which is probably a reﬂection of their other comorbid
conditions. Overall, we found comparable treatment between
blacks and whites. This encouraging news is consistent with
recent research illustrating that racial disparities in ICD
therapy have declined over time.41
An important ﬁnding was racial differences in medication
adherence. Although other investigative teams have found
that blacks were more likely than whites to report running out
of medications and not following provider instructions on
medication administration,14,42 this is the ﬁrst study to
document racial differences in medication adherence mea-
sured objectively. Racial differences have been attributed to
disparities in health insurance,43,44 health literacy,45 patient-
provider communication,44,46 self-efﬁcacy, depression, and
difﬁculty accessing providers.44 We found that neither health
insurance, income, education, premorbid intellect, number of
Table 3. Continued
Variable
n (%)
P Value*Black White
ICD therapy (n=220) 0.262
Yes 44 (59.5) 98 (67.1)
No 30 (40.5) 48 (32.9)
ACE indicates angiotensin-converting-enzyme; HF, heart failure; ICD, implantable cardioverter deﬁbrillator.
*Reported P-values are for associated v2 tests unless otherwise indicated.
†Using Fisher’s exact test.
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Table 4. Clinical Treatment Variables by Race for Patients With Heart Failure Preserved Ejection Fraction
Variable
n (%)
P Value*Black White
Primary physician provider a HF specialist (n=52) 0.575
Yes 10 (45.5) 16 (53.3)
No 12 (54.5) 14 (46.7)
Total number of medications prescribed to be taken daily (n=52) 0.026
>8 17 (77.3) 14 (46.7)
≤8 5 (22.7) 16 (53.3)
Receiving specialized HF services (n=52) 0.931
Yes 12 (54.5) 16 (53.3)
No 10 (45.5) 14 (46.7)
Receiving home health or visiting nursing care (n=52) 0.149†
Yes 4 (18.2) 1 (3.3)
No 18 (81.8) 29 (96.7)
Prescribed an ACE inhibitor (n=52) 0.375
Yes 10 (45.5) 10 (33.3)
No 12 (54.5) 20 (66.7)
Prescribed an aldosterone receptor antagonist (n=52) 0.167
Yes 3 (13.6) 9 (30.0)
No 19 (86.4) 21 (70.0)
Prescribed an angiotension receptor blocker (n=52) 0.717
Yes 7 (31.8) 11 (36.7)
No 15 (68.2) 19 (63.3)
Prescribed an ACE inhibitor and an angiotension receptor blocker (n=52) 0.888
Yes 15 (68.2) 21 (70.0)
No 7 (31.8) 9 (30.0)
Prescribed a beta blocker (n=52) 0.169†
Yes 15 (68.2) 26 (86.7)
No 7 (31.8) 4 (13.3)
Prescribed hydrazaline and isorbide dinitrate (n=52) 0.070†
Yes 3 (13.6) 0 (0)
No 19 (86.4) 30 (100)
Prescribed digoxin (n=52) 0.033†
Yes 0 (0) 6 (20.0)
No 22 (100) 24 (80.0)
Prescribed a diuretic with NYHA functional class II to IV (n=52) 0.016†
Yes 21 (95.5) 20 (66.7)
No 1 (4.5) 10 (33.3)
Prescribed warfarin (n=52) 0.056
Yes 4 (18.2) 13 (43.3)
No 18 (81.8) 17 (56.7)
Continued
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medications, nor depression fully explained racial differences
in medication adherence. Medication adherence is inﬂuenced
by the number and frequency of pills taken daily,47 with
estimates of a 10% decline in adherence with each additional
daily medication dose.48,49 In our study, although more blacks
than whites took more than 8 medications per day, the
number of medications prescribed did not explain medication
adherence. Only renal disease helped to explain lower
Table 4. Continued
Variable
n (%)
P Value*Black White
ICD therapy (n=52) 0.476
Yes 6 (27.3) 11 (36.7)
No 16 (72.7) 19 (63.3)
ACE indicates angiotensin-converting-enzyme; HF, heart failure; ICD, implantable cardioverter deﬁbrillator.
*Reported P values are for associated v2 tests unless otherwise indicated.
†Using Fisher’s exact test.
Table 5. Heart Failure Self-Care Variables by Race
Variable
n (%)
P Value*Black White
HF knowledge (n=262) 0.002
DKHFS≤10 29 (32.6) 27 (15.6)
DKHFS>10 60 (67.4) 146 (84.4)
SCHFI maintenance score (n=268) 0.627
<70 51 (54.3) 89 (51.1)
≥70 43 (45.7) 85 (48.9)
SCHFI management score (n=122)† 0.091
<70 20 (40.0) 40 (55.6)
≥70 30 (60.0) 32 (44.4)
SCHFI confidence score (n=272) 0.923
<70 30 (31.3) 56 (31.8)
≥70 66 (68.7) 120 (68.2)
Reporting trouble breathing or ankle swelling in past month item (n=272) 0.077
Yes 50 (52.1) 72 (40.9)
No 46 (47.9) 104 (59.1)
Urinary sodium (n=221) 0.597
≥3.5 50 (68.5) 105 (70.9)
≥2.1 and <3.5 14 (19.2) 31 (21.0)
<2.1 9 (12.3) 12 (8.1)
MEMS medication adherence (n=212) <0.001
<88% PDT 48 (77.4) 77 (51.3)
≥88% PDT 14 (22.6) 73 (48.7)
Exercise (n=272) <0.001
<30 min/week 54 (56.3) 52 (29.5)
≥30 min/week 42 (43.7) 124 (70.5)
DKHFS indicates Dutch Knowledge of Heart Failure Scale; HF, heart failure; MEMS, Medication Event Monitoring System; PDT, prescribed doses taken; SCHFI, Self-Care Heart Failure Index.
*Reported P values are for associated v2 tests.
†Only collected from patients reporting trouble breathing or ankle swelling in past month.
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adherence in addition to race. In other samples blacks with
renal disease were no less adherent to their medications than
blacks without renal disease.50 Further research is needed to
understand the persistence of racial differences in medication
adherence even after adjusting for sociodemographic and
clinical characteristics as well as clinical treatment variables.
Knowledge of HF has been shown to be lower in blacks than
whites.51 Few investigators have measured intellect, but low
health literacy and poor educational attainment have been
associated with lower levels of knowledge about HF and poor
self-care.52–54 Low levels of formal education and poor health
literacy are common inminority populations,which suggests that
low HF knowledge in blacks may reﬂect the need for tailored
education that takes into account intellect, literacy, and formal
education.55 Screening for health literacymay provide important
information that could help to tailor the treatment regimen.
Two factors contributed in important ways to clinical
treatment and self-care: premorbid intellect (discussed in
relation to knowledge above) and social support. Perceived
quality of support was a signiﬁcant determinant for 2 clinical
treatments—the prescription of ACE inhibitors and H-ISDN.
The importance of support for successful self-care has been
well established.56 Black patients with HF who lack sufﬁcient
support may be particularly challenged by the demands of
daily self-care, and our results suggest that providers are
taking this fact into account when prescribing therapy. We
were surprised that multimorbidity was not a signiﬁcant factor
in self-care. We demonstrated previously that HF patients with
multimorbidity receive fragmented self-care instructions that
impede their ability to perform self-care21 and decrease their
conﬁdence.20 However, in this study, comorbidity was not a
signiﬁcant determinant of self-care in the blacks with higher
numbers of comorbid conditions.
Although we found blacks to be more likely to be
depressed than whites, depression did not inﬂuence clinical
treatment or self-care. This was surprising because depres-
sion has been shown previously to affect HF self-care.57
People who are depressed are less likely to engage in health
practices such as smoking cessation or regular exercise.58
The reason why depression had little inﬂuence on self-care
was probably because patients with major depression were
screened out at enrollment so the racial differences in
depression reﬂected relatively minor differences.
Limitations of this study include primarily cross-sectional
nature of the data and the secondary analysis. In addition, our
analysis by HF type is limited by the small sample sizes,
especially for patients with HFpEF. Although self-care was
measured in a robust manner, the dataset was not built with
the intention of describing clinical treatment so most of the
variables were abstracted from the medical record rather than
Table 6. Adjusted Results for Clinical Treatment and Self-Care Variables with Signiﬁcant Unadjusted Racial Differences*
Racial Difference
Supplementary Predictors†n P OR (95%CI)
Clinical treatment variables
For HFrEF patients
Prescribed an ACE inhibitor 219 0.008 0.45 (0.25 to 0.81) Satisfactory social support quality
Prescribed H-ISDN 215 0.041 3.37 (1.05 to 10.8) Good social support quality, history of renal disease
Prescribed a diuretic with NYHA functional class II to IV 210 0.508 — ANART≤25, history of renal disease
For HFpEF patients
>8 medications 52 0.034 4.21 (1.12 to 15.9) History of diabetes mellitus
Prescribed digoxin‡ 52 0.016 — —
Prescribed a diuretic with NYHA functional class II to IV 52 0.032 10.5 (1.23 to 89.7) —
Self-care variables
For HFrEF and HFpEF patients
DKHFS≤10 261 0.001 3.03 (1.62 to 5.68) History of myocardial infarction
% prescribed dose taken <88% 200 0.003 2.99 (1.47 to 6.09) History of renal disease
Exercise <30 min/week 267 0.092 — ANART≤25, history of renal disease
ACE indicates angiotensin-converting-enzyme; ANART, American National Adult Reading Test; CI, conﬁdence interval; DKHFS, Dutch Heart Failure Knowledge Scale; H-ISDN, hydrazaline
and isosorbide dinitrate; HFpEF, preserved ejection fraction HF; HFrEF, reduced ejection fraction HF; OR, odds ratio; NYHA, New York Heart Association.
*Results for Wald v2 tests using logistic regression models unless otherwise indicated.
†Chosen from among the variables of Tables 1 and 2 for analyses of clinical treatment variables and from among the variables of Tables 1 and 2 and the common variables of Tables 3 and
4 for analyses of self-care variables.
‡Results for Fisher’s exact test since no blacks were prescribed digoxin, and so no OR reported.
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being collected speciﬁcally for this study. The medical record is
known to be an imprecise record of reality.59 Categorizing
continuous variables may have resulted in a loss of information,
but categorizations were based on common criteria used with
these variables so that reported results are based on
meaningful categorizations. In addition, recruitment was
limited to northeastern United States. Variations in HF care
have been documented in different parts of the country, so
our results should be interpreted with caution for populations
outside of this region of the United States.. Further, there may
be social factors that contribute to the disease burden
experienced by blacks that we did not measure.
In conclusion, although numerous racial differences in
sociodemographic and clinical characteristics were found in
this study, few of these factors inﬂuenced either clinical
treatment or patient self-care. This encouraging news sug-
gests that providers are successfully overcoming previously
identiﬁed disparities in care, at least in the HF population.
However, the ﬁndings that blacks had deﬁcits in HF knowl-
edge and decreased medication adherence are disturbing.
Further efforts are needed to personalize HF care, support
improvements in self-care strategies, and support policies
aimed at health equity.
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